YIELD OF BAL IN PATIENTS RECEIVING IMMUNE CHECK POINT INHIBITORS

Immune Check Point Inhibitors in Cancer Therapy: Beware of "Friendly Fire" Effect.

Immune Check Point Inhibitors in Cancer Therapy: Beware of “Friendly Fire” Effect Anuhya Kommalapati1, Shanaz Sikder2 and Sri Harsha Tella3* 1Department of Internal Medicine, Washington Hospital Center, Washington DC, USA 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, USA 3Eunice Kennedy Shriver National Institutes of Child Health and Human Development...

Novel Immune Check-Point Regulators in Tolerance Maintenance

The great success of anti-cytotoxic lymphocyte antigen 4 (CTLA4) and anti-programed cell death protein 1 (PD1) in cancer treatment has encouraged more effort in harnessing the immune response through immunomodulatory molecules in various diseases. The immunoglobulin (Ig) super family comprises the majority of immunomodulatory molecules. Discovery of novel Ig super family members has brought nov...

Targeted therapy of ovarian cancer including immune check point inhibitor

Epithelial ovarian cancer is the eighth most common cause of cancer-related deaths in women because most patients present with advanced stage disease at the time of diagnosis. Although cytoreductive surgery and platinum-based chemotherapy remain the gold standards of treatment, the recurrence rate of ovarian cancer remains high. Attempts to improve this standard two-drug chemotherapy by adding ...

The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study

Immune checkpoint inhibitors (ICI) are revolutionizing care for cancer patients. The list of malignancies for which the Food and Drug Administration is granting approval is rapidly increasing. Furthermore, there is a concomitant increase in clinical trials incorporating ICI. However, the safety of ICI in patients undergoing surgery remains unclear. Herein, we assessed the safety of ICI in the p...

Image guided cryoablation of cancer with intra-tumoral injection of anti-CTLA-4 and PD-1 immune check-point inhibitors